『AML Hub』のカバーアート

AML Hub

AML Hub

著者： Scientific Education Support
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Scientific Education Support
エピソード
  • Targeting menin: A paradigm shift in acute myeloid leukemia therapy

    Targeting menin: A paradigm shift in acute myeloid leukemia therapy
    2026/10/13

    Steering committee meeting


    In August, 2026, the AML Hub held a steering committee meeting where Joshua Zeidner presented on Targeting menin: A paradigm shift in acute myeloid leukemia therapy, followed by a panel discussion.


    This podcast is independently supported by Kura Oncology. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    34 分
  • FLT3 inhibitors in AML: Current clinical landscape and key insights from trials

    FLT3 inhibitors in AML: Current clinical landscape and key insights from trials
    2026/07/01

    The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gained from trials so far?


    Levis provides an overview of the key FLT3 inhibitors in clinical development for the treatment of FLT3-mutated (FLT3m) AML and discusses ongoing questions, including how to select the most appropriate FLT3 inhibitor for different patient populations and how best to incorporate them into standard treatment regimens. He highlights the value of measurable residual disease (MRD) in monitoring disease status as an important insight from clinical trials.


    This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    5 分
  • Future directions for FLT3 inhibitors in AML treatment

    Future directions for FLT3 inhibitors in AML treatment
    2026/06/30

    The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of AML?


    Stein summarizes the approved indications for currently available FLT3 inhibitors and considers potential future directions for their investigation in the treatment of acute myeloid leukemia (AML), including in combination regimens and in patients with FLT3-ITD-negative AML.


    This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    4 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません